YMAB: Y-mAbs Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 519.11
Enterprise Value ($M) 450.98
Book Value ($M) 92.43
Book Value / Share 2.06
Price / Book 5.62
NCAV ($M) 70.57
NCAV / Share 1.58
Price / NCAV 7.36

Profitability (mra)
Return on Invested Capital (ROIC) -0.26
Return on Assets (ROA) -0.19
Return on Equity (ROE) -0.24

Liquidity (mrq)
Quick Ratio 3.54
Current Ratio 3.92

Balance Sheet (mrq) ($M)
Current Assets 99.06
Assets 120.92
Liabilities 28.49
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
3 days ago 13G/A Paradigm Biocapital Advisors LP 9.20 85.89
5 days ago 13G/A Vanguard Group Inc 4.56 0.00
02-14 13G/A WG Biotech ApS 10.70 9.18
02-13 13G/A HBM Healthcare Investments (Cayman) Ltd. 7.60 -13.53
02-06 13G/A Acorn Bioventures, L.p. 6.30 18.71
01-26 13G/A BlackRock, Inc. 6.70 13.12

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 114,363 616,544 18.55
2024-11-14 86,574 357,156 24.24
2024-11-13 40,772 189,421 21.52
2024-11-12 66,269 238,021 27.84
2024-11-11 59,320 262,760 22.58

(click for more detail)

Similar Companies
XBIT – XBiotech Inc. XERS – Xeris Biopharma Holdings, Inc.
XLO – Xilio Therapeutics, Inc. ZVRA – Zevra Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io